Junrou Technology Raises Nearly $15M in Angel+ Round for Brain-Computer Interfaces

Junrou Technology, a Shenzhen-based startup developing invasive brain-computer interface hardware, announced an Angel+ financing on November 2, 2026, equivalent to nearly $15 million. Shunwei Capital led the round, joined by Hillhouse Ventures, embodied-AI company AgiBot and Nansha Qisheng. The $15 million figure is an approximate USD conversion of the amount described in the company's Chinese-language financing report, not a separately disclosed dollar-denominated raise.

What Junrou is building

Founded in 2025, Junrou develops flexible neural electrodes, signal-processing algorithms and motion-control methods for future brain-computer interfaces. Its flagship research platform, NeuroWorm, uses a magnetically controlled flexible fiber electrode designed to move after implantation, potentially enabling measurements from multiple brain regions without repeated electrode placement. The company describes an electrode only about 100 micrometers across, but these design characteristics are not clinical efficacy results.

Junrou also applies its flexible sensing materials to tactile sensors and electronic skin for robotic hands. This offers a second potential commercial market, but device manufacturing, integration and repeatable robot performance remain to be proven.

Financing and investors

Shunwei Capital led the Angel+ financing, with Hillhouse Ventures, AgiBot and Nansha Qisheng joining, according to the November 2 original report. Junrou intends to use the proceeds to finalize NeuroWorm electrode processes, establish GMP-oriented production lines, advance animal studies and further develop neural-signal algorithms.

Reports also describe multiple financings since the company's foundation. Do not confuse the total across earlier rounds with the separately announced Angel+ amount; the exact capital raised in each prior transaction has not been established here.

Why it matters

Junrou sits at the intersection of medical neural interfaces and embodied robotics. If the NeuroWorm platform succeeds, movable electrodes could change how clinicians monitor or stimulate more than one brain region. On the robotics side, stretchable tactile sensing could improve manipulation where cameras alone do not provide enough physical feedback.

Those are technical possibilities, not evidence of an approved medical device or of commercial revenue. Investors should watch for peer-reviewed validation, reproducible animal safety data, manufacturing yields, regulatory milestones and named commercial partners.

Funding amount and currency methodology

VCT reports financing in USD or EUR only. The approximate nearly $15 million equivalent uses the European Central Bank reference rates from October 30, 2026, the latest published reference fixing available before the November 2 announcement: 1 euro = $1.1172. The dollar conversion is rounded to avoid suggesting a precise deal size that the source did not disclose.

Company profile

See the Junrou Technology startup profile for the structured financing history and linked investment event.